A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

2000 British Journal of Cancer 929 citations

Abstract

A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse. Primary objectives were to determine progression-free survival (PFS) at 6 months and safety for TMZ and PCB in adult patients who failed conventional treatment. Secondary objectives were to assess overall survival and health-related quality of life (HRQL). TMZ was given orally at 200 mg/m2/day or 150 mg/m2/day (prior chemotherapy) for 5 days, repeated every 28 days. PCB was given orally at 150 mg/m2/day or 125 mg/m2/day (prior chemotherapy) for 28 days, repeated every 56 days. HRQL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 [+3]) and the Brain Cancer Module 20 (BCM20). The 6-month PFS rate for patients who received TMZ was 21%, which met the protocol objective. The 6-month PFS rate for those who received PCB was 8% (P = 0.008, for the comparison). Overall PFS significantly improved with TMZ, with a median PFS of 12.4 weeks in the TMZ group and 8.32 weeks in the PCB group (P = 0.0063). The 6-month overall survival rate for TMZ patients was 60% vs. 44% for PCB patients (P = 0.019). Freedom from disease progression was associated with maintenance of HRQL, regardless of treatment received. TMZ had an acceptable safety profile; most adverse events were mild or moderate in severity. © 2000 Cancer Research Campaign

Keywords

TemozolomideMedicineProcarbazineInternal medicineChemotherapyAdverse effectQuality of life (healthcare)Phases of clinical researchCancerDacarbazineProgression-free survivalOncologySurgeryVincristineCyclophosphamide

MeSH Terms

AdultAgedAntineoplastic AgentsAntineoplastic AgentsAlkylatingBrain NeoplasmsDacarbazineDisease-Free SurvivalFemaleGlioblastomaGliosarcomaHumansMaleMiddle AgedProcarbazinePrognosisQuality of LifeRecurrenceTemozolomideTime Factors

Affiliated Institutions

Related Publications

Publication Info

Year
2000
Type
article
Volume
83
Issue
5
Pages
588-593
Citations
929
Access
Closed

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

929
OpenAlex
27
Influential
742
CrossRef

Cite This

W.K. Alfred Yung, Robert E. Albright, Jeffrey J. Olson et al. (2000). A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. British Journal of Cancer , 83 (5) , 588-593. https://doi.org/10.1054/bjoc.2000.1316

Identifiers

DOI
10.1054/bjoc.2000.1316
PMID
10944597
PMCID
PMC2363506

Data Quality

Data completeness: 86%